Prior to co-founding Alacrita, Anthony was CEO of Onyvax, an immune-oncology company he co-founded in 1997, raising more than ￡35 million from blue chip life science investors including 3i and S.R. One.
Before Onyvax, he spent 10 years as a management consultant at Arthur D Little (where he was appointed a European Director and led the London-based pharmaceutical practice) and at The Wilkerson Group in London. He consulted to big pharma, diagnostics companies and biotech, and also produced expert reports for five IPOs.
Anthony holds an Honors degree in Natural Sciences and a PhD in Biochemistry from the University of Cambridge. He is a Fellow of the Royal Society of Biology and Chairman of the Strand Chamber Orchestra.
He specializes in strategy and due diligence.
Recent projects he has conducted or directed include: